AbbVie’s RINVOQ shows promise in Vitiligo Phase 3 trials
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva
Sourced and formulated in the United States, Ameriflor Calm is derived from plants grown on regenerative organic certified farms and is manufactured at a site that uses 100% renewable electricity
Merck will showcase results in innovative solutions in HIV treatment and prevention
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
Subscribe To Our Newsletter & Stay Updated